• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

目前正在每日口服暴露前预防药物(PrEP)的男男性行为者(MSM)中,获取长效注射用暴露前预防药物(LA-PrEP)的地点偏好。

Location Preferences for Accessing Long-Acting Injectable Pre-Exposure Prophylaxis (LA-PrEP) Among Men Who Have Sex With Men (MSM) Currently on Daily Oral PrEP.

作者信息

Glick Jennifer L, Nestadt Danielle F, Sanchez Travis, Li Kevin, Hannah Marissa, Rawlings M Keith, Rinehart Alex R, Sarkar Supriya, Vannappagari Vani

机构信息

Community Health Science & Policy (CHSP), Louisiana State University, Health Sciences Center, New Orleans, LA, USA.

Department of Health, Behavior and Society, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.

出版信息

J Int Assoc Provid AIDS Care. 2024 Jan-Dec;23:23259582241293336. doi: 10.1177/23259582241293336.

DOI:10.1177/23259582241293336
PMID:39698980
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11788811/
Abstract

We investigated men who have sex with men's (MSM) location preferences for long-acting injectable pre-exposure prophylaxis (LA-PrEP). MSM ( = 1076) who completed the 2021 American Men's Internet Survey, were currently prescribed oral PrEP, and expressed LA-PrEP interest reported location preferences for receiving LA-PrEP: healthcare provider (HCP) setting, pharmacy, or at-home. HCP settings were preferred by 60% of participants; 26% preferred home and 14% preferred pharmacy. In adjusted models, high healthcare stigma was associated with preferring pharmacy and at-home versus HCP, while high friends/family stigma was associated with preferring HCP settings versus pharmacy. Healthcare access history was associated with preference for HCP setting versus home. Being 25 to 29 or 30 to 29 years old versus 40+ was associated with preferring HCP versus home. Private insurance was associated with location preferences. Findings support the need for multiple LA-PrEP service locations to best reach MSM and highlight multiple complex factors that influence such preferences.

摘要

我们调查了男男性行为者(MSM)对长效注射用暴露前预防(LA-PrEP)的地点偏好。完成2021年美国男性互联网调查、目前正在服用口服PrEP并表示对LA-PrEP感兴趣的1076名男男性行为者报告了接受LA-PrEP的地点偏好:医疗保健提供者(HCP)机构、药房或在家中。60%的参与者更喜欢HCP机构;26%的人更喜欢在家中,14%的人更喜欢药房。在调整模型中,较高的医疗保健污名与更喜欢药房和在家中接受注射而非HCP机构相关,而较高的朋友/家庭污名与更喜欢HCP机构而非药房相关。医疗保健获取史与更喜欢HCP机构而非在家中接受注射相关。与40岁及以上相比,25至29岁或30至39岁的人更喜欢HCP机构而非在家中接受注射。私人保险与地点偏好相关。研究结果支持需要多个LA-PrEP服务地点以最好地覆盖男男性行为者,并突出了影响此类偏好的多个复杂因素。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f147/11788811/85a03d1d1655/10.1177_23259582241293336-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f147/11788811/85a03d1d1655/10.1177_23259582241293336-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f147/11788811/85a03d1d1655/10.1177_23259582241293336-fig1.jpg

相似文献

1
Location Preferences for Accessing Long-Acting Injectable Pre-Exposure Prophylaxis (LA-PrEP) Among Men Who Have Sex With Men (MSM) Currently on Daily Oral PrEP.目前正在每日口服暴露前预防药物(PrEP)的男男性行为者(MSM)中,获取长效注射用暴露前预防药物(LA-PrEP)的地点偏好。
J Int Assoc Provid AIDS Care. 2024 Jan-Dec;23:23259582241293336. doi: 10.1177/23259582241293336.
2
Intention to Use Pre-Exposure Prophylaxis Among Age Groups of Brazilian Men Who Have Sex With Men: National Cross-Sectional Study.巴西男男性行为者各年龄组使用暴露前预防药物的意向:全国横断面研究
JMIR Public Health Surveill. 2025 Jul 8;11:e58405. doi: 10.2196/58405.
3
Men's Voices on Long-Acting Pre-Exposure Prophylaxis Delivery Modalities: Acceptability and Preferences Among Cisgender Men and Men Who Have Sex With Men in South Africa.男性对长效暴露前预防给药方式的看法:南非顺性别男性和男男性行为者的可接受性及偏好
J Acquir Immune Defic Syndr. 2025 May 1;99(1):55-63. doi: 10.1097/QAI.0000000000003638.
4
Awareness and intention to use event-driven and long-acting injectable pre-exposure prophylaxis among adolescent and young men who have sex with men and transgender women in Brazil: a cross-sectional study.巴西男男性行为者和跨性别女性中青少年对事件驱动型和长效注射用暴露前预防药物的知晓率及使用意愿:一项横断面研究
J Int AIDS Soc. 2025 Jul;28 Suppl 2(Suppl 2):e26479. doi: 10.1002/jia2.26479.
5
Optimising HIV pre-exposure prophylaxis and testing strategies in men who have sex with men in Australia, Thailand, and China: a modelling study and cost-effectiveness analysis.在中国、澳大利亚和泰国优化男男性行为者的 HIV 暴露前预防和检测策略:一项建模研究和成本效益分析。
Lancet Glob Health. 2024 Feb;12(2):e243-e256. doi: 10.1016/S2214-109X(23)00536-3.
6
Preferences for on-demand/intermittent/event-driven and long-acting injectable (LAI) HIV pre-exposure prophylaxis (PrEP) among HIV-negative Black gay, bisexual, and other sexual minority men in the United States: A qualitative study.美国 HIV 阴性的黑人男同性恋者、双性恋者及其他性少数男性对按需/间歇性/事件驱动型和长效注射用艾滋病毒暴露前预防(PrEP)的偏好:一项定性研究。
PLoS One. 2025 Jun 30;20(6):e0323212. doi: 10.1371/journal.pone.0323212. eCollection 2025.
7
Understanding barriers to HIV pre-exposure prophylaxis initiation among men who have sex with men in Sindh, Pakistan.了解巴基斯坦信德省男男性行为者开始接受艾滋病毒暴露前预防的障碍。
Int J STD AIDS. 2025 Jul;36(8):649-654. doi: 10.1177/09564624251344419. Epub 2025 May 21.
8
Preferences and willingness to use pre-exposure prophylaxis for HIV among men who have sex with men in mainland China and Hong Kong.中国大陆和香港男男性行为者对艾滋病病毒暴露前预防用药的偏好及使用意愿。
Sex Health. 2025 May;22. doi: 10.1071/SH24247.
9
Preferences for Monthly Oral PrEP Over Other PrEP Modalities Among a National Sample of Gay, Bisexual, and Other Men Who Have Sex With Men in the United States.美国男同性恋、双性恋及其他与男性发生性关系的男性全国样本中,对每月口服暴露前预防药物(PrEP)相较于其他PrEP方式的偏好。
J Acquir Immune Defic Syndr. 2025 Jun 1;99(2):128-137. doi: 10.1097/QAI.0000000000003651.
10
High Preference for Injectable Pre-exposure Prophylaxis among Young Women in Kenya.肯尼亚年轻女性对注射用暴露前预防药物的高度偏好。
AIDS Behav. 2025 Mar 24. doi: 10.1007/s10461-025-04687-x.

本文引用的文献

1
Measuring sexual behavior stigma among cisgender men who have sex with men: an assessment of cross-country measurement invariance.测量与男性发生性关系的顺性别男性中的性行为污名:跨国测量不变性评估。
Stigma Health. 2024 Aug;9(3):349-361. doi: 10.1037/sah0000443. Epub 2023 May 4.
2
Delivering HIV prevention medication online: Findings from a qualitative study exploring the acceptability of an online HIV pre-exposure prophylaxis (PrEP) care pathway among service users and healthcare professionals.在线提供艾滋病毒预防药物:一项定性研究的结果,该研究探讨了服务使用者和医疗保健专业人员对在线艾滋病毒暴露前预防(PrEP)护理途径的可接受性。
Digit Health. 2023 Nov 30;9:20552076231217816. doi: 10.1177/20552076231217816. eCollection 2023 Jan-Dec.
3
Variation in Preferences for Long-Acting Injectable Pre-Exposure Prophylaxis Among US Men Who Have Sex with Men: A Latent Class Analysis.美国男男性行为者对长效注射型暴露前预防用药偏好的差异:潜在类别分析。
AIDS Patient Care STDS. 2023 Oct;37(10):495-503. doi: 10.1089/apc.2023.0109.
4
Systematic review of the values and preferences regarding the use of injectable pre-exposure prophylaxis to prevent HIV acquisition.系统评价关于使用注射用暴露前预防措施预防 HIV 感染的价值观和偏好。
J Int AIDS Soc. 2023 Jul;26 Suppl 2(Suppl 2):e26107. doi: 10.1002/jia2.26107.
5
The Future of Pre-Exposure Prophylaxis (PrEP) for HIV Prevention: A Global Qualitative Consultation on Provider Perspectives on New Products and Differentiated Service Delivery.用于预防HIV的暴露前预防(PrEP)的未来:关于提供者对新产品和差异化服务提供的观点的全球定性咨询。
AIDS Behav. 2023 Nov;27(11):3755-3766. doi: 10.1007/s10461-023-04093-1. Epub 2023 Jun 23.
6
Exploring preferences and decision-making about long-acting injectable HIV pre-exposure prophylaxis (PrEP) among young sexual minority men 17-24 years old.探讨 17-24 岁年轻性少数男性对长效注射型 HIV 暴露前预防(PrEP)的偏好和决策。
Sci Rep. 2023 Mar 29;13(1):5116. doi: 10.1038/s41598-023-32014-8.
7
Willingness to use and preferences for long-acting injectable PrEP among sexual and gender minority populations in the southern United States, 2021-2022: cross-sectional study.2021-2022 年美国南部性少数群体和性别少数群体对长效注射型 PrEP 的使用意愿和偏好:横断面研究。
J Int AIDS Soc. 2023 Mar;26(3):e26077. doi: 10.1002/jia2.26077.
8
Estimating the impact of HIV PrEP regimens containing long-acting injectable cabotegravir or daily oral tenofovir disoproxil fumarate/emtricitabine among men who have sex with men in the United States: a mathematical modelling study for HPTN 083.评估含长效注射用卡博特韦或每日口服替诺福韦酯/恩曲他滨的HIV暴露前预防方案在美国男男性行为者中的影响:HPTN 083的数学建模研究
Lancet Reg Health Am. 2023 Jan 17;18:100416. doi: 10.1016/j.lana.2022.100416. eCollection 2023 Feb.
9
Injectable Long-Acting Cabotegravir-Rilpivirine Therapy for People Living With HIV/AIDS: Addressing Implementation Barriers From the Start.注射用长效卡替拉韦/利匹韦林治疗艾滋病毒/艾滋病患者:从一开始就解决实施障碍。
J Assoc Nurses AIDS Care. 2023;34(2):216-220. doi: 10.1097/JNC.0000000000000386. Epub 2023 Jan 20.
10
Association of anticipated HIV testing stigma and provider mistrust on preference for HIV self-testing among cisgender men who have sex with men in the Philippines.菲律宾男男性行为者对 HIV 自检偏好与预期 HIV 检测污名和提供者不信任的关联。
BMC Public Health. 2022 Dec 16;22(1):2362. doi: 10.1186/s12889-022-14834-x.